Advertisement
UK markets close in 21 minutes

  • FTSE 100

    8,043.68
    +19.81 (+0.25%)
     

  • FTSE 250

    19,767.83
    +168.44 (+0.86%)
     

  • AIM

    754.94
    +5.76 (+0.77%)
     

  • GBP/EUR

    1.1625
    +0.0036 (+0.31%)
     

  • GBP/USD

    1.2434
    +0.0084 (+0.68%)
     

  • Bitcoin GBP

    53,759.28
    +787.03 (+1.49%)
     

  • CMC Crypto 200

    1,439.26
    +24.50 (+1.73%)
     

  • S&P 500

    5,057.02
    +46.42 (+0.93%)
     

  • DOW

    38,434.47
    +194.49 (+0.51%)
     

  • CRUDE OIL

    82.39
    +0.49 (+0.60%)
     

  • GOLD FUTURES

    2,334.10
    -12.30 (-0.52%)
     

  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     

  • HANG SENG

    16,828.93
    +317.24 (+1.92%)
     

  • DAX

    18,115.06
    +254.26 (+1.42%)
     

  • CAC 40

    8,100.89
    +60.53 (+0.75%)
     
Money:

What is the true cost of the UK state pension?

To get a sense of the true value of the state pension, you can look at how much you would need to save to match it yourself

4 big analyst picks: Norfolk Southern stock pops on 2 upgrades

Investing.com
·2-min read

Here is your Pro Recap of the biggest analyst picks you may have missed today: upgrades at Norfolk Southern, DraftKings, Union Pacific, and AnaptysBio.

InvestingPro subscribers got this news before anyone else. Start your 7-day trial to get on board.

Norfolk Southern garners 2 upgrades

Norfolk Southern (NYSE:NSC) shares rose more than 2% pre-market today after two Wall Street firms upgraded the company, as InvestingPro reported in real time.

Wells Fargo upgraded the company to Overweight from Equal Weight and raised its price target to $250.00 from $225.00. Meanwhile, Citi upgraded to Buy from Neutral and raised its price target to $257.00 from $226.00.

ADVERTISEMENT

Last month, the company reported its Q1 earnings, highlighted by an EPS beat and in-line revenues.

DraftKings shares surge 3% on UBS upgrade

UBS upgraded DraftKings (NASDAQ:DKNG) to Buy from Neutral and raised its price target to $30.00 from $19.00. Shares gained more than 3% pre-market today.

Earlier this month, the company reported its Q1 results, with both EPS and revenues coming in better than the Street estimates.

2 more upgrades

Citi upgraded Union Pacific (NYSE:UNP) to Buy from Neutral and raised its price target to $237.00 from $229.00. Shares rose more than 1% pre-market today.

JPMorgan upgraded AnaptysBio (NASDAQ:ANAB) to Neutral from Underweight while slightly lowering its price target to $30.00 from $31.00, noting it doesn’t see significant downside risk from current levels, given near and intermediate-term focus is on clinical execution for lead programs rather than catalysts - ANB032 and rosnilimab.

On the other hand, the firm doesn’t see upside potential from the core pipeline, while noting that it's important to monitor competition for each of the aforementioned mechanisms/products. This balance forms the basis of its Neutral rating, and the firm expects AnaptysBio shares to perform in line with biotech peers.

In fast-moving markets, every second counts - and InvestingPro subscribers are always one step ahead with lightning-quick updates.

Start your free 7-day trial now.

Related Articles

4 big analyst picks: Norfolk Southern stock pops on 2 upgrades

Ford signs battery material supply deals to charge up EV output

Morgan Stanley sees signals of panic buying in S&P 500, ongoing rally 'a head fake'